Duality Advisers LP acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to its most recent filing with the SEC. The firm acquired 25,500 shares of the company’s stock, valued at approximately $1,801,000. Duality Advisers LP owned about 0.06% of Omnicell as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in OMCL. Norges Bank bought a new position in Omnicell in the 4th quarter valued at $30,171,000. Bank of New York Mellon Corp boosted its position in Omnicell by 62.3% in the 1st quarter. Bank of New York Mellon Corp now owns 877,992 shares of the company’s stock valued at $57,578,000 after buying an additional 337,035 shares during the last quarter. Ziegler Capital Management LLC bought a new position in Omnicell in the 1st quarter valued at $10,100,000. State Street Corp boosted its position in shares of Omnicell by 8.1% in the 1st quarter. State Street Corp now owns 1,303,978 shares of the company’s stock worth $85,515,000 after purchasing an additional 97,154 shares during the last quarter. Finally, Waddell & Reed Financial Inc. grew its stake in shares of Omnicell by 16.6% during the first quarter. Waddell & Reed Financial Inc. now owns 637,803 shares of the company’s stock worth $41,827,000 after purchasing an additional 90,934 shares during the period. Hedge funds and other institutional investors own 95.79% of the company’s stock.
In other Omnicell news, EVP Scott Peter Seidelmann sold 2,125 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $67.70, for a total transaction of $143,862.50. Following the completion of the transaction, the executive vice president now owns 33,385 shares of the company’s stock, valued at approximately $2,260,164.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Randall A. Lipps sold 3,718 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $75.15, for a total value of $279,407.70. Following the transaction, the chief executive officer now directly owns 152,116 shares of the company’s stock, valued at approximately $11,431,517.40. The disclosure for this sale can be found here. 2.63% of the stock is currently owned by corporate insiders.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, July 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. Omnicell had a return on equity of 9.21% and a net margin of 5.42%. The business had revenue of $199.62 million during the quarter, compared to analysts’ expectations of $182.16 million. During the same period in the prior year, the business earned $0.67 EPS. Omnicell’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts anticipate that Omnicell, Inc. will post 1.68 EPS for the current fiscal year.
Several equities analysts have weighed in on OMCL shares. Cantor Fitzgerald increased their target price on Omnicell from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday. ValuEngine cut Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, April 17th. Benchmark lowered their price target on Omnicell from $96.00 to $82.00 and set a “buy” rating for the company in a research note on Friday, May 8th. BidaskClub cut Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, July 8th. Finally, Piper Sandler lowered their price target on Omnicell from $76.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $85.50.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Bond
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.